Collaboration will focus on development of a companion diagnostic (CDx) for Vitrakvi^®, the first-in-class tyrosine kinase (TRK) inhibitor approved in the U.S. and Europe for adult pediatric patients with TRK fusion cancer across all solid tumors. Vitrakvi has the largest and longest-term data set in TRK fusion cancer.*

Goal is to advance broad patient access to comprehensive genomic testing through kit-based CDx that can be deployed locally at the site of care in line with Bayer’s commitment to advancing precision oncolytics.

Find out more.